Utilization of stored autologous PBSCs to support second autologous transplantation in multiple myeloma patients in the era of novel agent therapy

Bone Marrow Transplantation
C PhippsE Libby

Abstract

Outcomes in multiple myeloma (MM) have improved significantly with novel agent therapy and autologous stem cell transplantation (ASCT). ASCTs are typically planned as either tandem or a single transplant with additional stored PBSCs available for a second salvage transplant. To accommodate these strategies, many centers routinely collect and store adequate PBSCs for two ASCTs. We analyzed the cost associated with this practice by determining the expenses of PBSC collection, cryopreservation and storage, and the ultimate use of additional cryopreserved PBSCs in patients who had undergone at least one ASCT. There were 889 MM patients transplanted between 1993 and 2011 at our center. Most (N=726) had residual PBSCs in storage after their first ASCT (ASCT1). Only 135 patients underwent a second ASCT within a median of 14 months after ASCT1. The percentage of patients receiving a second ASCT declined over time. The resources required to collect and store unused PBSCs added up to 336 extra patient days of apheresis and 41 587 extra patient months of cryopreservation, translating into an average extra cost per patient of US$4981.12. A reconsideration of conventional PBSC collection and storage practices would save significant cost for...Continue Reading

References

Nov 24, 1999·The New England Journal of Medicine·S SinghalB Barlogie
May 9, 2003·The New England Journal of Medicine·J Anthony ChildUNKNOWN Medical Research Council Adult Leukaemia Working Party
Dec 26, 2003·The New England Journal of Medicine·Michel AttalUNKNOWN InterGroupe Francophone du Myélome
Jul 29, 2006·Blood·Michel AttalUNKNOWN Inter-Groupe Francophone du Myélome (IFM)
May 9, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Michele CavoMichele Baccarani
Oct 14, 2008·Bone Marrow Transplantation·R L OlinE A Stadtmauer
Nov 10, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Josien C RegelinkSonja Zweegman
Nov 9, 2011·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Victor H Jimenez-ZepedaDonna E Reece
May 11, 2012·The New England Journal of Medicine·Philip L McCarthyCharles Linker
May 11, 2012·The New England Journal of Medicine·Michel AttalUNKNOWN IFM Investigators
Jul 18, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Pieter SonneveldHartmut M Goldschmidt
Nov 29, 2012·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Emilie LemieuxPhilippe Moreau
Jan 10, 2013·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Laura C MichaelisUNKNOWN Plasma Cell Disorders Working Committee of the Center for International Blood and Marrow Transplant Research
Jan 12, 2013·Journal of the National Comprehensive Cancer Network : JNCCN·Kenneth C AndersonRashmi Kumar
May 28, 2013·Bone Marrow Transplantation·H W AunerUNKNOWN Plasma Cell Dyscrasia Sub-committee of the Chronic Malignancies Working Party of the European Group for Blood and Marrow Tra
Aug 21, 2013·Annals of Oncology : Official Journal of the European Society for Medical Oncology·P MoreauUNKNOWN ESMO Guidelines Working Group

❮ Previous
Next ❯

Citations

Jul 28, 2020·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Saurabh ChhabraMehdi Hamadani
Sep 24, 2018·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Katharina KriegsmannPatrick Wuchter
May 20, 2020·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Felix KrummradtKatharina Kriegsmann

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.